GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Shiller PE Ratio

Gilead Sciences (Gilead Sciences) Shiller PE Ratio

: 10.18 (As of Today)
View and export this data going back to 1992. Start your Free Trial

As of today (2024-04-16), Gilead Sciences's current share price is $67.31. Gilead Sciences's E10 for the quarter that ended in Dec. 2023 was $6.61. Gilead Sciences's Shiller PE Ratio for today is 10.18.

The historical rank and industry rank for Gilead Sciences's Shiller PE Ratio or its related term are showing as below:

GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.93   Med: 15.02   Max: 77.37
Current: 10.18

During the past years, Gilead Sciences's highest Shiller PE Ratio was 77.37. The lowest was 9.93. And the median was 15.02.

GILD's Shiller PE Ratio is ranked better than
87.02% of 516 companies
in the Drug Manufacturers industry
Industry Median: 24.075 vs GILD: 10.18

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.140. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $6.61 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Shiller PE Ratio Historical Data

The historical data trend for Gilead Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.62 11.58 12.80 13.87 12.26

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.87 13.13 12.02 11.39 12.26

Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Shiller PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.



Gilead Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=67.31/6.61
=10.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.14/129.4194*129.4194
=1.140

Current CPI (Dec. 2023) = 129.4194.

Gilead Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 1.330 99.695 1.727
201406 2.200 100.560 2.831
201409 1.670 100.428 2.152
201412 2.180 99.070 2.848
201503 2.760 99.621 3.586
201506 2.920 100.684 3.753
201509 3.060 100.392 3.945
201512 3.180 99.792 4.124
201603 2.530 100.470 3.259
201606 2.580 101.688 3.284
201609 2.490 101.861 3.164
201612 2.340 101.863 2.973
201703 2.050 102.862 2.579
201706 2.330 103.349 2.918
201709 2.060 104.136 2.560
201712 -2.960 104.011 -3.683
201803 1.170 105.290 1.438
201806 1.390 106.317 1.692
201809 1.600 106.507 1.944
201812 0.002 105.998 0.002
201903 1.540 107.251 1.858
201906 1.470 108.070 1.760
201909 -0.920 108.329 -1.099
201912 2.120 108.420 2.531
202003 1.220 108.902 1.450
202006 -2.660 108.767 -3.165
202009 0.290 109.815 0.342
202012 1.230 109.897 1.449
202103 1.370 111.754 1.587
202106 1.210 114.631 1.366
202109 2.050 115.734 2.292
202112 0.300 117.630 0.330
202203 0.020 121.301 0.021
202206 0.910 125.017 0.942
202209 1.420 125.227 1.468
202212 1.300 125.222 1.344
202303 0.800 127.348 0.813
202306 0.830 128.729 0.834
202309 1.730 129.860 1.724
202312 1.140 129.419 1.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (NAS:GILD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Gilead Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (Gilead Sciences) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Executives
Andrew D Dickinson officer: EVP, Chief Financial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier officer: Chief Commercial Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey officer: Chief Medical Officer 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson officer: SVP, Controllership 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong officer: SVP, Controller & CAO 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman officer: EVP, Corporate Affairs & GC 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher officer: EVP, Gen Counsel & Corp Sec 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters director
Javier Rodriguez director 601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan director 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson director C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711

Gilead Sciences (Gilead Sciences) Headlines